Wealthcare Advisory Partners’s GSK GSK Stock Holding History

Wealthcare Advisory Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,815	Closed	-$208K	–	612
2022 Q2	$208K	Buy	3,815 +21	+0.6%	+$1.16K	0.01%	522
2022 Q1	$207K	Sell	3,794 -222	-6%	-$12.1K	0.01%	511
2021 Q4	$221K	Buy	+4,016	New	+$209K	0.01%	521
2021 Q2	–	Sell	-3,820	Closed	-$170K	–	1081
2021 Q1	$170K	Buy	+3,820	New	+$173K	0.01%	519
2020 Q2	–	Sell	-1,542	Closed	-$73K	–	757
2020 Q1	$73K	Sell	1,542 -1,991	-56%	-$106K	0.01%	432
2019 Q4	$207K	Buy	3,533 +254	+8%	+$14.1K	0.03%	294
2019 Q3	$175K	Sell	3,279 -350	-10%	-$18K	0.03%	294
2019 Q2	$182K	Buy	3,629 +448	+14%	+$22.5K	0.03%	283
2019 Q1	$166K	Sell	3,181 -35	-1%	-$1.75K	0.03%	265
2018 Q4	$154K	Buy	3,216 +199	+7%	+$9.8K	0.03%	249
2018 Q3	$151K	Sell	3,017 -168	-5%	-$8.54K	0.03%	262
2018 Q2	$160K	Buy	3,185 +329	+12%	+$16.6K	0.03%	250
2018 Q1	$139K	Buy	2,856 +1,276	+81%	+$59.4K	0.03%	234
2017 Q4	$70K	Sell	1,580 -1,236	-44%	-$57.1K	0.02%	321
2017 Q3	$143K	Buy	2,816 +2,681	+1,986%	+$136K	0.04%	174
2017 Q2	$7K	Buy	+135	New	+$7.2K	﹤0.01%	84

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Wealthcare Advisory Partners's GSK Position: Q3 2022 in Review

Wealthcare Advisory Partners sold out of GSK (GSK) in Q3 2022, closing a stake of 3,815 shares — an estimated $208K sold.

Wealthcare Advisory Partners first reported a position in GSK in Q2 2017 and held it in 16 quarters. The position peaked at $221K in Q4 2021. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

Wealthcare Advisory Partners reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
Wealthcare Advisory Partners sold 3,815 GSK shares in Q3 2022, an estimated $208K.
Wealthcare Advisory Partners first reported a position in GSK in Q2 2017 and held it in 16 quarters.
Wealthcare Advisory Partners's GSK position peaked at $221K in Q4 2021.
742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Wealthcare Advisory Partners's 13F filing for Q3 2022, filed 14 Nov 2022.